Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review

The role of renin‐angiotensin‐aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID‐19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID‐19 and explored reasons for discrepancies in the literature.

V. Gaborieau | A. Sommet | R. Favory | J. Payen | D. Luton | Y. Yazdanpanah | S. Rebaudet | J. Timsit | L. Lefebvre | H. Le Nagard | N. Benech | D. Costagliola | J. Hulot | L. Abel | L. Bouadma | M. Esposito‐Farèse | J. Lucet | P. Rossignol | E. L’her | H. Mouquet | L. Plantier | C. Tromeur | R. Borie | C. Flateau | S. Diamantis | M. Jourdain | A. Kimmoun | A. Guillaumot | F. Retornaz | L. Bodénes | L. Mandelbrot | B. Cholley | D. Deplanque | S. Nseir | K. Faure | F. Djossou | J. Lelièvre | M. Rosa-Calatrava | B. Lina | A. Gaymard | S. van der Werf | B. Dussol | E. Vidal-Petiot | D. Malvy | F. Lescure | V. Enouf | J. Mullaert | N. Néant | G. Peytavin | D. Descamps | B. Rammaert | C. Ficko | E. D’Ortenzio | S. Thiberville | A. Scherpereel | G. Martin-Blondel | P. Delobel | M. Debray | A. Khalil | B. Sarton | J. Guedj | R. Basmaci | O. Launay | H. Esperou | F. Bissuel | N. Peiffer-Smadja | François Téoulé | D. Guellec | K. Lacombe | B. Pastene | Q. Le Hingrat | M. Mezidi | V. Gissot | A. Sotto | J. Poissy | P. Tattevin | E. Botelho-Nevers | A. Gagneux-Brunon | P. Bolze | F. Mentré | A. Chéret | V. Lemée | O. Lairez | S. Ansart | J. Arlet | T. Flament | A. Wiedemann | X. Duval | J. Dimet | M. Le Maréchal | Paul-Henri Wicky | C. Couffignal | A. Boureau | D. Garot | L. Guilleminault | I. Gorenne | M. Lagrange | V. Le Moing | S. Le Gac | H. Cordel | S. Jauréguiberry | S. Redl | C. Rabaud | L. Bitker | É. Senneville | S. Préau | L. Piroth | J. Inamo | F. Angoulvant | J. Diehl | D. Zucman | L. Bouillet | O. Terrier | O. Bouchaud | N. Ouamara | N. Terzi | O. Lesens | H. Salvator | C. Laouénan | F. Goehringer | A. Cabié | B. Visseaux | W. Picard | S. Greffe | O. Epaulard | M. Maillet | C. Semaille | C. Chirouze | C. Andrejak | O. Picone | C. Salmon Gandonnière | S. Tubiana | P. Loubet | O. Robineau | D. Laureillard | T. Goulenok | L. Maulin | Q. Lepiller | C. Tardivon | Victoria Manda | E. de Montmollin | C. Roy | V. Garrait | J. Sibiude | E. Polard | K. Bouiller | B. Lefebvre | F. Kaguelidou | T. Perpoint | P. Roger | C. Rapp | A. Ducancelle | J. Turmel | B. Rozé | F. Dubos | J. Ghosn | É. Demonchy | K. Risso | Y. Kerroumi | V. Meyssonnier | L. Deconinck | S. Bessis | F. Vuotto | V. Dubée | A. Meybeck | Théo Trioux | C. Allavena | G. Colin | C. Tual | A. Veislinger | M. Revest | H. Hitoto | M. Martinot | N. Sedillot | H. Yonis | A. Lemaignen | A. Conrad | N. Dournon | M. Doret‐Dion | K. Didier | D. Bachelet | Stella Rousset | V. Langlois | G. Louis | V. Peigne | E. Curlier | M. Livrozet | M. Isnard | J. Jabot | C. Dorival | F. Bompart | K. Alexandre | M. Etienne | A. Bousquet | D. Bregeaud | J. Chapplain | D. Ponscarme | M. Hentzien | G. Le Moal | A. Diallo | J. Assié | C. Yelnik | A. Debard | Minerva Cervantes-Gonzalez | R. Mahieu | P. Le Turnier | M. Bouscambert | D. Larivière | E. Mercier | S. Markowicz | K. Delavigne | E. Oziol | S. Le Mestre | Aurélie Papadopoulos | G. Macheda | F. Bani-Sadr | T. Guimard | O. Sanchez | H. Aumaître | Bruno Lévy | I. Fabre | Marielly Casanova | M. Leone | J. Patrier | Duc Nguyen | J. Mankikian | M. Murris | M. Blot | S. Mahy | J. Chas | R. Guery | H. Drouet | D. Bouhour | M. Lachâtre | S. Bévilacqua | R. Hamidfar | P. Rispal | M. Roriz | N. Gault | M. Lambert | Charlène Da Silveira | K. Bhavsar | L. Luong | N. Saidani | I. Hoffmann | N. Mercier | Valentine Campana | N. Ferrière | V. Pestre | Adrien Auvet | N. Allou | B. Elharrar | T. Carmoi | C. Azoulay | Marie Bartoli | Sylvie Behilill | Marine Beluze | D. Benkerrou | Anissa Chair | A. Coelho | Mathilde Desvallée | P. Eloy | Tristan Gigante | M. Gilg | Alexandre Hoctin | I. Houas | S. Jaafoura | Ouifiya Kafif | Sabrina Kali | Coralie Khan | F. Lainé | Samira Laribi | Minh Lê | Cyril Le Bris | G. Lingas | Moïse Machado | Marina Mambert | Al Manuel | Amina Meziane | Marion Noret | C. Paul | Oriane Puéchal | Bénédicte Rossignol | M. Schneider | N. Vanel | C. Vauchy | P. Dunand | Cécile Goujard | I. Delacroix | M. Gominet | Justine Pages | S. Bouchez | S. Stabler | C. Joseph | E. Soum | Y. Ait Tamlihat | Johann Auchabie | Laurène Azemar | Claudine Badr | Jules Bauer | A. Bedossa | K. Bézulier | Anne‐Hélène Boivin | Axelle Braconnier | M. Buisson | Cyril Cadoz | Nicolas Carlier | F. Catherine | Catherine Chakveatze | Thibault Chiarabini | Marie‐Charlotte Chopin | Grégory Corvaisier | S. Cousse | Corinne Daniel | Romain Decours | Eric Delaveuve | V. Dinot | Fara Diop | I. Enderle | Nadia Ettalhaoui | Eglantine Ferrand Devouge | E. Fourn | R. Gaci | J. Gagnard | G. Giordano | Laure Goubert | A. Hachemi | Hajnal-Gabriela Illes | P. Imbert | Danielle Jaafar | Coline Jaud‐Fischer | Florence Jego | A. Kpangon | M. Lacoste | S. Lasry | C. Le Bihan | G. Le Falher | B. Lefèvre | A. Lemeur | Geoffrey Liegeon | Oryane Mabiala | T. Maitre | Thierry Mazzoni | Antoine Merckx | Clara Mouton Perrot | J. Moyet | Elsa Nyamankolly | R. Ouissa | M. Pagadoy | N. Pansu | J. Pasquier | Florent Peelman | Carola Pierobon | I. Pironneau | R. Pokeerbux | Anne-Sophie Resseguier | L. Richier | J. Romaru | Stéphane Sallaberry | Nassima Si Mohammed | Lysa Tagherset | B. Thill | N. Tissot | T. Trouillon | Jeanne Truong | A. Valran | N. De Castro | Mayka Mergeayfabre | Lucie Lefèvre | Marie‐Christine Carret | Guylaine Castor‐Alexandre | T. Chiarabini | S. Couffin‐Cadiergues | R. Courtois | Hajnal‐Gabriela Illes | Marie Langelot‐Richard | Cécile Mear‐Passard | V. Petrov‐Sanchez | S. Rousset | Pierre‐François Sandrine | Marie‐Capucine Tellier | Matthieu Lesouhaitier | C. Rames | Camille Bouisse | M. Bennani | Aurélie Martin | A. Barrelet | A. Diouf | S. Fry | B. Loutfi | Y. N’Guyen | Yves Lévy | P. Granier | B. Lefévre | J. Zabbe | Camille Chassin | E. Le Coustumier | Marie Alpha Soizic Noémie Christelle Ventzislava Claire Bartoli Diallo Le Mestre Mercier Paul Petro | Claire Léy‐Marchal | Maximilen Saint Gilles | Céline Michelangelli | Pierre Jacquet | Elise Artaud‐Maccari | Marie‐Laure Chabi‐Chavillat | P. Caraux Paz | J. Auchabie | M. Noret | M. Esposito-farese | S. Couffin-cadiergues | M. Machado | Cécile Azoulay | S. Laribi | V. Petrov-sanchez | Juliette Patrier | Rostane Gaci | Simon-djamel Thiberville | Maïder Pagadoy | A. Auvet | Hervé Le Nagard | Muriel Doret‐Dion | Karine Bézulier | C. Goujard | Marie Lacoste | Isabelle Pironneau | Ryadh Pokeerbux | Amélie Valran | Laurent Guilleminault | N. Peiffer‐Smadja | Samuel Markowicz | Dehbia Benkerrou | A. Chair | Fanny Vuotto | O. Puéchal | M. Tellier | C. Laouénan | Charléne Da Silveira | Romain Basmaci | Charlotte Salmon Gandonnière | Vincent Pestre | Jimmy Mullaert | Mehdi Mezidi

[1]  P. Whelton,et al.  Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies , 2021, Journal of hypertension.

[2]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[3]  T. Chang,et al.  Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.

[4]  L. Lund,et al.  Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis , 2020, European journal of heart failure.

[5]  B. Hocher,et al.  Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis , 2020, British journal of clinical pharmacology.

[6]  J. Rigdon,et al.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.

[7]  A. Sommet,et al.  Outcome of patients hospitalized for COVID‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: results of the ACE‐CoV study , 2020, Fundamental & clinical pharmacology.

[8]  Y. Yazdanpanah.  Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients , 2020, Journal of medical virology.

[9]  V. Vassiliou,et al.  Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients , 2020, Current Atherosclerosis Reports.

[10]  J. Moslehi,et al.  Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients , 2020, Journal of the American Heart Association.

[11]  Jesús Piqueras-Flores,et al.  Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection , 2020, Medicina Clínica (English Edition).

[12]  A. Singer,et al.  Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome , 2020, The Journal of infectious diseases.

[13]  D. D. de Lange,et al.  Inhibitors of the renin–angiotensin–aldosterone system and COVID-19 in critically ill elderly patients , 2020, European heart journal. Cardiovascular pharmacotherapy.

[14]  R. Cianci,et al.  Age and Multimorbidity Predict Death Among COVID-19 Patients , 2020, Hypertension.

[15]  C. Torp‐Pedersen,et al.  Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.

[16]  A. Grover,et al.  A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers , 2020, European heart journal. Cardiovascular pharmacotherapy.

[17]  Y. Mahjoub,et al.  Association between renin–angiotensin system inhibitors and COVID-19 complications , 2020, European heart journal. Cardiovascular pharmacotherapy.

[18]  A. Daugherty,et al.  Effects of Renin-Angiotensin Inhibition on ACE2 and TMPRSS2 Expression: Insights into COVID-19 , 2020, bioRxiv.

[19]  G. Condorelli,et al.  Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality , 2020, European heart journal. Cardiovascular pharmacotherapy.

[20]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[21]  A. Pickles,et al.  Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust , 2020, European journal of heart failure.

[22]  Yuan Hong,et al.  Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis. , 2020, Hypertension.

[23]  Sun-Young Jung,et al.  Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Jiong Yu,et al.  ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis , 2020, Pharmacological Research.

[25]  L. Rodríguez-Mañas,et al.  Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.

[26]  P. Ponikowski,et al.  Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors , 2020, European heart journal.

[27]  J. Sterne,et al.  Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.

[28]  Sung Yang,et al.  Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea , 2020, Hypertension.

[29]  M. Chung,et al.  Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[30]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[31]  C. Borghi,et al.  Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Jian Chen,et al.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[33]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[34]  Qingbo Xu,et al.  Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.

[35]  Ji-Guang Wang,et al.  Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 , 2020, Cardiovascular research.

[36]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[37]  J. Ge,et al.  The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension , 2020, Annals of translational medicine.

[38]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[39]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[40]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[41]  Haitao Chu,et al.  Effect estimates in randomized trials and observational studies: comparing apples with apples. , 2019, American journal of epidemiology.

[42]  S. Cole,et al.  Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.

[43]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[44]  D. Batlle,et al.  Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. , 2009, American journal of physiology. Renal physiology.

[45]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[46]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[47]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[48]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[49]  Yun-Cai Liu,et al.  Association of the , 1995 .